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Aim: Recent studies raise concerns for higher incidence of hepatocellular carcinoma (HCC) after direct-
acting antiviral therapy for hepatitis C virus (HCV). Methods: In this study, using analysis of liver imaging
pre- and post-DAA treatment, we queried new occurrence or ‘de novo’ of HCC in patients with HCV-
cirrhosis treated with DAAs. Of 150 patients who met study criteria, 7 (4.7%; 95% CI: 2.1–9.5%) patients
developed de novo HCC which did not differ from historical rates of 3% (p = 0.22). Results: Notably,
patients with decompensated cirrhosis had significantly higher rate of de novo HCC (9.3%; 95% CI: 3.12–
22.2%; p = 0.04). Conclusion: Our data support the need for continued surveillance for HCC in HCV cir-
rhotics even after successful therapy.
First draft submitted: 22 January 2018; Accepted for publication: 4 May 2018; Published online:
25 July 2018
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Hepatitis C virus (HCV) infection affects nearly 3 million individuals in the USA [1] and up to 185 million affected
patients worldwide [2,3]. Deaths due to HCV complications have risen since 2010 and will likely continue to
increase over the next several years [4]. In patients infected with HCV, about 20% will eventually develop liver
cirrhosis, and a substantial proportion of those will go on to develop hepatocellular carcinoma (HCC) [5]. HCC is
the fifth most common type of cancer worldwide and is the second leading cause of cancer-related deaths [6].
The majority of HCC cases are found in patients with cirrhosis of the liver [7]. For patients chronically infected
with HCV, the progression to cirrhosis is promoted by HCV-induced inflammation. While HCV infection is the
strongest risk factor for development of HCC, other risk factors include male sex, coinfection with hepatitis B
virus or HIV, alcohol consumption and older age. Of HCC cases in the USA, 50–60% are secondary to HCV.
It is estimated that the annual incidence of HCC development after cirrhosis develops is about 1–4%, with a
time-period of roughly 20 years from initial HCV infection to development of HCC without any treatment [7].
During the past several years, major innovations have been made in the HCV treatment realm, with new direct-
acting antiviral (DAA) regimens achieving greater than a 90% sustained virologic response (SVR) rate for most
viral genotypes. Studies have shown rates of SVR around 97% in compensated cirrhotics [8–10] and up to 90% in
patients with more advanced liver disease, some even awaiting transplant [11,12]. These therapies are taken orally
and are interferon-free, virtually eliminating the significant side effects of interferon therapy that once represented
a large barrier to successful treatment. The increased effectiveness and tolerability of the new class of drugs allows
for treatment of patients with much more advanced disease [13].
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Previous interferon-based regimens have been shown to possibly decrease the risk of developing new HCC and
to decrease rate of recurrence [14,15]. Currently, data are conflicting on the impact of DAAs on the development of
HCC. Several studies showed that patients infected with HCV who have received treatment with DAA remain at
risk for HCC and with potential increased risk for recurrence, ranging from 6.6 to 9.1% [16–20]. Conversely, other
studies showed reductions in HCC occurrence after achievement of SVR fromDAA-containing therapies [21–24]. In
a large study of over 60,000 patients receiving combinations of interferon only, DAA+interferon and DAA only,
SVR was again associated with a significantly decreased risk of HCC irrespective of the type of treatment. DAA
treatment was found to be associated with 71% risk reduction of development of HCC [22].
A systematic review and meta-analysis also found that DAA therapy was not associated with higher HCC
occurrence. Higher incidence of HCC was observed in older patients and with shorter follow-up periods [24]. In
view of these conflicting reports, we specifically investigated the new occurrence of HCC in patients with HCV
cirrhosis who underwent treatment with DAAs, utilizing radiologic evaluation for lesions pre- and post-treatment.
Methods
Patient population
This retrospective, single-center study investigated the development of de novoHCC in patients with HCV cirrhosis
who received treatment with a DAA-containing regimen at University of California, Davis Health (CA, USA) from
1 January, 2014 to 1 April, 2017. Institutional Review Board approval was obtained. Patients were included in
the study if they met the following criteria: age ≥18 years; had chronic hepatitis C; had cirrhosis as defined by
either clinical status, labs, imaging, FIB-4 score or a combination of these; treated with DAA-containing regimen;
had liver-directed imaging (screening ultrasound, CT scan or MRI) up to 12 months prior to treatment; had
liver-directed imaging 12 months postcompletion of DAA treatment and if any lesion was detected, patient needed
to have 4-phase CT scan or dynamic MRI to be in the final cohort. Patients were excluded if they met the following
criteria: minors; fibrosis/METAVIR Stage 0–3; patients without both pre- and post-imaging within 12 months of
treatment or without dynamic imaging, if any lesion was detected; incarcerated patients; pregnant patients; prior
history of liver transplant and presence of LI-RADS 4–5 lesions prior to receiving DAA therapy.
Study objectives
The primary objective of the study was to determine new occurrence of HCC as defined as LIRADS 4 or 5 after
completion of HCV treatment with DAA-based regimens. Imaging was either screening ultrasound, CT scan or
MRI. If there was a lesion that was identified on those imaging studies, a multiphase CT or MRI was then required
to define HCC. Two independent reviewers performed a retrospective chart review of these patients to determine
if there was ‘no’, ‘new’ or ‘pre-existent’ HCC. The secondary objectives of the study evaluated linkage to genotype,
SVR or regimen for the occurrence of DAAs. HCC was defined by radiologic criteria on multiphase imaging either
as definite HCC or LIRADS 4/5 on the radiology report. A radiologist would review any conflicts on LIRADs
classification.
Hepatitis C antiviral treatment
All patients underwent HCV treatment with a DAA-based regimen for either 12 or 24 weeks as indicated by the
American Association for the Society of Liver Diseases/Infectious Diseases and Society of America HCV treatment
guidelines. Treatment regimen selection was chosen at that discretion of the physician. Baseline characteristics,
laboratory values, radiologic tumor response were recorded prior to initiation of antiviral therapy.
Time-points for radiologic evaluation of tumor
Radiological studies, either abdominal ultrasound, 4-phase CT scan or MRI were evaluated for each study partici-
pant at two time points. The first evaluation for HCC was within the 12-month period prior to initiation of DAA
treatment. All dynamic images between 12 months prior to the start of treatment were reviewed to evaluate for any
pre-existing lesion. The second time-point was within 12 months after the end of treatment.
Statistical analysis
The data were analyzed by a statistician as a noninferiority study. The exact binomial test was used to test for
statistical significance. Confidence intervals for proportions were calculated using the Agresti–Coull method [25].
Hepat. Oncol. (2018) 5(1) future science group
De novo HCC with DAA treatment in HCV patients Research Article
409 patients with HCV Cirrhosis
treated with direct-acting antivirals
177 patients with both pre-
and post-therapy imaging
232 patients excluded – did not have
both pre and post-therapy imaging
24 patients excluded – 1. Prior
history of HCC 2. Evidence of prior
 locoregional therapy on imaging
3. Patients lost to follow-up
150 patients qualified for the study with no
prior history of HCC and with both pre- and
post-treatment imaging (with dynamic
imaging, if any lesion)
Figure 1. Study enrollment. This flowchart depicts the study inclusion and exclusion criteria utilized to select the
patient population.
Proportions were comparedwith a historical proportion of 3%using an exact binomial test. Analyses were conducted
using the statistical software environment R, version 3.4.1 [26] and the R package binom, version 1.1–1 [27].
Results
Demographics
From 1 January 2014 to 1 April 2017, 409 patients with cirrhosis were treated with a DAA-containing regimen at
the University of California, Davis Health. Of these patients, 150 met the inclusion criteria as shown in Figure 1.
A total of 146 patients were treated with an all-oral DAA regimen, whereas four patients were treated with
sofosbuvir, interferon and ribavirin. The majority of the patients included in the study were males (59%), with
compensated cirrhosis (71%) and infected with HCV genotype 1 (77%). Half of the patients were treated with a
sofosbuvir/ledipasvir-containing regimen and the most patients achieved SVR (93%) (Table 1).
New HCC occurrence after DAA completion
Seven of 150 patients (4.67%; CI: 2.1–9.5) developed de novo HCC within 12 months from completion of HCV
treatment. Of the seven patients, six were noted to have LIRADS 5 and one with LIRADS 4 lesion on multiphase
imaging. These patients had pretreatment imaging 12 months prior to starting treatment with DAAs that did
not show any evidence of HCC. When compared with historical rates of 3% for new HCC occurrence in HCV
cirrhosis, the observed rate in this study was not considered statistically different (p-value = 0.224). For patients
treated with an all-oral DAA regimen, the rate of de novoHCCdevelopment slightly increased to 4.79% (n = 7/146,
CI (2.16–9.74%) and was also not statistically different from the historical rate (p-value = 0.215).
New lesions were mostly identified within 0–6 months post-treatment (n = 5/7; 71.4%). No new lesions
were identified during the HCV treatment. The majority of patients were HCV treatment naive prior to the
DAA-containing therapy (n = 5/7; 71.4%) and 57% of patients (n = 4/7) had decompensated cirrhosis. Patients
developing de novo HCV were either infected with HCV genotype 1A, 3 or 6. All patients achieved SVR12
(Table 2).
Rates of de novoHCCwere significantly higher in patients with decompensated cirrhosis at 9.3%when compared
with historical rates of 3% (p-value = 0.040) and were threefold higher than rates observed compensated cirrhosis,
9.3% compared with 2.8%, respectively. While rates of de novo HCC were observed to be higher in patients who
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Table 1. Patient demographics.
Primary characteristics Sub-characteristics n Total percentage
Overall – 150 100
Viral response SVR 140 93
Relapse 10 7
Gender Male 89 59
Female 61 41
Race/ethnicity Asian 3 2
Black/African-American 6 4
Hispanic 6 4
White 46 31
Unknown 89 59
BMI 25 43 29
25–29.9 50 33
30–35 33 22
35 23 15
No data 1 1
HCV genotype 1 115 77
2 11 7
3 19 13
4 1 1
6 4 3
Compensation Compensated 107 71
Decompensated 43 29
Treatment regimen SOF+LDV +/-RBV 74 49
SIM+SOF+/-RBV 33 22
SOF+RBV 20 13
GRZ+ELB 6 4
SOF+DCV +/-RBV 8 5
SOF+VEL+/-RBV 5 3
SOF+PEG-IFN+RBV 4 3
Treatment history Naive 87 58
Experienced (IFN or IFN/DAA) 63 42
BMI: Body mass index; DAA: Direct-acting antiviral ; DCV: Daclatasvir; ELB: Elbasvir; GRZ: Grazoprevir; HCV: Hepatitus c virus; IFN: Interferon; LDV: Ledipasvir; PEG: Pegylated; RBV: Ribavirin;
SIM: Simeprevir; SOF: Sofosbuvir; SVR: Sustained virologic response.
were treatment-naive prior to receiving the DAA-containing therapy or infected with HCV genotype 1A, 3 or 6,
the differences were not statistically significant compared with historical rates (Table 3).
Discussion
HCC is a potentially fatal complication of HCV-related cirrhosis with an annual incidence rate around 3.5% [20].
Prior to the advent of DAA-therapies, HCV treatment with PEG-IFN and RBV was associated with a decreased
risk for HCC development. De novoHCC rates in patients treated with IFN who achieve SVR have been reported
to be 0.5–2% over 3 years post-treatment [15,28–31]. This benefit was anticipated to translate to the direct-acting
agents; however, several studies suggest that there may be an increase in rates of de novo and recurrent HCC after
HCV treatment with DAAs. Reported rates of de novoHCC status post DAA-based therapy have ranged from 6.6%
to 9.1% [16–20]. However, these studies did have limitations, as they were mostly small, retrospective, uncontrolled
studies with short-term follow-up. Additionally, their sample population was drawn from patients at higher risk
of HCC, such as over age 60 or already with liver failure. More recent studies suggest either no change in the
rate of HCC after successful HCV treatment with DAA therapies or a similar decrease compared with IFN-based
regimens [21–24]. In two larger retrospective studies, the risk of HCC was reduced by 71–76% in patients who
achieved SVR being treated with DAA-containing regimen [21,22]. In the study conducted by the Veterans Health
Administration, patients with cirrhosis were found to have the highest risk of HCC [21]. Moreover, a systematic
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Table 2. Characteristics of patients with de novo hepatocellular carcinoma occurrence.
Primary characteristics Sub-characteristics n % total
Overall new HCC 7 4.7%
Age 40–70 7 100%
Gender Male 4 57.1%
Female 3 42.9%
Cirrhosis Compensated 3 43.0%
Decompensated 4 57.0%
Laboratory values at baseline
ALT ≤40 4 57%
40 3 43%
Platelet ≤150 6 86%
150 1 14%
Time to diagnosis of new HCC 0–6 months post-treatment 5 71.4%
7–12 months post-treatment 2 28.6%
LIRADs classification LIRADS 4 6 86%
LIRADS 5 1 14%
HCV genotype 1 4 2.6%
3 2 1.3%
6 1 0.7%
Treatment status Treatment-naive 5 71.4%
Treatment-experienced (IFN or
IFN/DAA)
2 28.6%
Treatment response SVR 7 100%
ALT: Alanine aminotransferase; DAA: Direct-acting anitiviral; HCC: Hepatocellular carcinoma; HCV: Hepatitus C virus; IFN: Interferon; LIRADS: Liver reporting and data system; SVR:
Sustained virologic response.
Table 3. Rates of de novo hepatocellular carcinoma per patient populations.
Group Number of new HCC Total number of patients Rate (95% CI) p-value †
Treatment-naive 5 87 5.75% (2.16%, 13.07%) 0.192
Treatment-experienced 2 63 3.17% (0.23%, 11.50%) 0.714
Compensated 3 107 2.80% (0.61%, 8.27%)  0.999
Decompensated 4 43 9.30% (3.12%, 22.16%) 0.040
Male 4 89 4.49% (1.41%, 11.35%) 0.345
Female 3 61 4.92% (1.14%, 14.03%) 0.433
GT 1a 4 77 5.19% (1.64%, 13.00%) 0.296
GT 3 2 19 10.53% (1.70%, 32.63%) 0.110
GT 6 1 4 25.00% (3.41%, 71.09%) 0.115
†p-value of  0.05 is considered statistically significant from historical HCC rate of 3% (Bold font indicates that rates of de novo HCC were significantly higher in patients with decom-
pensated cirrhosis)
GT: Genotype; HCC: Hepatocellular carcinoma.
review and meta-analysis found that DAA therapy was not associated with higher HCC occurrence. Incidence of
HCC was lower in younger patients and in those patients who were followed for a longer period of time [24].
This study investigated the incidence of de novo HCC in cirrhotic patients, both compensated and decompen-
sated, who were treated with DAA-containing therapy and followed with radiologic imaging within 12months after
completion of HCV treatment. Overall, no significant difference was observed in rates of de novoHCC in patients
treated with DAA-containing therapy when compared with historical rates. While data are conflicting regarding
the impact of DAA-therapy on the rate of HCC, this study provides evidence that DAAs did not significantly
increase the risk for HCC. The caveat remains that the risk is not appreciably decreased compared with historical
rates or as noted with patients treated with interferon-based therapies.
As DAA therapy has a substantially improved safety profile compared with interferon, more complicated patients
are being treated for HCV, including those with decompensated cirrhosis. Interferon use is contraindicated in
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Child’s Turcotte Pugh Class B and C patients; thus, excluding these patients from the earlier studies evaluating the
rates of HCC development status post-treatment. In this study, patients with decompensated cirrhosis were found
to have a significantly higher rate of de novo HCC development at 9.3% compared with historical rates. Nearly
60% of the patients who developed de novo HCC had decompensated cirrhosis and the rate of de novo HCC
development in decompensated cirrhotic patients was threefold higher than in compensated cirrhotic patients,
9.3% compared with 2.8%, respectively.
Decompensated cirrhosis has been shown to be an independent risk factor for developing HCC and is possibly
contributing to the higher rates of HCC observed in cirrhotic patients treated withDAA-containing regimens [32,33].
Similar to the data presented in this study, a surveillance program conducted in 313 Italian patients with cirrhosis of
differing etiologies identified Child Pugh Class B/C as an independent risk factor the development of HCC, with
patients having a threefold increased risk [32]. In a prospective study in 400 Chinese patients with either hepatitis
B or HCV cirrhosis, Child Pugh Class B was also associated with a threefold increased risk while Child Pugh Class
C was associated with a eightfold higher risk of developing HCC [33].
Time to new HCC lesion identification occurred after completion of DAA-containing therapy for all seven
patients developing de novo HCC in this study. For the majority of these patients, identification occurred within
0–6 months after HCV treatment; thus, highlighting the importance of continued HCC monitoring every 6
months for HCV cirrhosis irrespective of the HCV treatment.
One of the key strengths of the study is rigorous definition of de novo HCC. Cirrhotic patients with ‘no prior
lesion’ by definition is only in patients without any prior HCC, either treated or untreated. Such a cohort will
be difficult to ascertain with electronic search criteria. Thus, imaging was reviewed of all pre- and post-treated
patients to evaluate for any lesions. Any patients with positive lesions needed to have a dynamic imaging to rule
out HCC. All patients with a post-treatment lesion were evaluated with two independent reviewers for any past
history of HCC by chart review and/or history of any HCC treatment noted by an ablation cavity on imaging.
This process helped in eliminating patients who would otherwise be considered a ‘recurrence’ with risk of altering
the true overall occurrence rate. The major limitation to this study is that it is a small, single-center retrospective
cohort with an uncontrolled design and brief follow-up period. Therefore, it is difficult to fully appreciate the
entire impact of DAA treatment on HCC risk. Larger studies with longer follow-up durations are needed to further
evaluate this long-term benefits and possible risk for DAA-containing therapies and their possible impact on HCC
development. Additionally, because our cohort was made up of entirely cirrhotic patients with higher baseline risk
of HCC development than their noncirrhotic counterparts, it is a possibility that our baseline risk may be skewed
above historical rates, that took into account cirrhotic and noncirrhotic patients. Further, our cohort of patients
with liver failure was quite heterogeneous, with 43/150 patients in decompensated cirrhosis. This could have led
any potential positive effects of DAA treatments being missed; however, given the lack of data from studies such as
ours, we argue that the historical rates used for comparison are still reasonable. We did not specifically investigate
whether other comorbidities such as nonalcoholic fatty liver disease or nonalcoholic steatohepatitis affected the
HCC occurrence but would be an excellent area of future research.
Conclusion
In conclusion, this study showed no increase in the rate of de novo HCC in HCV cirrhotic patients treated
with DAA-containing therapy during a 12-month monitoring window compared with historic rates; however,
patients with decompensated cirrhosis were found to have a significantly higher rate of new HCC occurrence. As
decompensated cirrhotic patients were excluded from earlier interferon studies, rates of HCC may be increased
in the DAA-treatment era given the new ability to treat patients with more advanced liver disease. This data
does support the continued need for routine HCC monitoring in HCV cirrhotic patients after receiving antiviral
therapy.
Future perspective
We believe that this topic will continue to be of interest over the next several years, with ongoing study and data
collection. As we collect long-term follow-up data on patients with HCV cirrhosis treated with DAAs, the risk
for HCC will be more apprehensible. Until we fully understand the risks for HCC, patients with HCV cirrhosis
should continue to be screened according to current national guidelines even after achieving viral eradication.
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Summary points
• Several conflicting studies have recently been published investigating rates of hepatocellular carcinoma (HCC)
occurrence after treatment of hepatitis C virus (HCV) with new oral direct acting antivirals (DAA) agents.
• While treatment of patients with HCV cirrhosis with novel DAAs have yielded good results in terms of achieving
sustained virologic response, the development of HCC in these patients is still unknown.
• To help address this question, this study investigated the development of de novo HCC in HCV cirrhotic patients
treated with DAAs in a small, single-center retrospective cohort study design.
• Patients with known HCV cirrhosis and liver-directed imaging at least 12 months prior to starting DAA treatment,
as well as up to 12 months after completion of DAA treatment were included in the study.
• Any patients with lesions prior to initiation of DAA treatment were excluded.
• Imaging studies were reviewed by two independent reviewers for development of a LiRADS 4 or 5 lesion.
• 4.6% of the patients developed HCC within 0–6 months after completion of DAA therapy.
• Overall, no significant difference was observed in rates of de novo HCC in patients treated with DAA-containing
therapy when compared with historical rates.
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